New to GLP-1 medications? This plain-English guide explains the main terms, brands and common discussion topics so you can ask better questions, understand other members’ experiences and follow the research.
What is GLP-1?
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in blood sugar regulation, satiety and appetite signaling. GLP-1 receptor agonists are medications designed to activate this pathway. Some are prescribed for type 2 diabetes; others have FDA-approved weight-management indications. Their use, evidence and product labels are not identical, even when a brand shares an active ingredient with another brand.
GLP-1 brand names and medication names
| Ingredient | Common brands | What to know |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Same ingredient appears across distinct products and labeled uses; formulations and instructions differ. |
| Tirzepatide | Mounjaro, Zepbound | Acts at GIP and GLP-1 receptors. Brand indications differ. |
| Liraglutide | Victoza, Saxenda | Earlier GLP-1 medicine available under separate branded indications. |
| Dulaglutide | Trulicity | GLP-1 receptor agonist used for type 2 diabetes. |
| Exenatide | Byetta, Bydureon | An earlier GLP-1 receptor agonist family. |
Generic names describe ingredients; brand names identify specific products. Avoid assuming that directions, strengths, indications or insurance coverage are interchangeable between products. Read the exact prescribing information for the product you have been prescribed.
Semaglutide: Ozempic, Wegovy and Rybelsus
Semaglutide is often discussed in relation to appetite, glucose, long-term weight management and treatment experience. Ozempic and Rybelsus have uses for type 2 diabetes, while Wegovy has weight-management indications and additional labeled uses. Some products are injectable and others oral. These differences matter when discussing experiences and possible side effects.
Discussion prompts: What did your clinician explain about your specific product? What terminology was confusing at first? Which practical questions would you ask at follow-up?
Tirzepatide: Mounjaro and Zepbound
Tirzepatide acts on both GIP and GLP-1 receptors. Mounjaro is associated with type 2 diabetes treatment; Zepbound has weight-management indications and other labeled uses. People may discuss appetite changes, gastrointestinal symptoms, costs, and access, but individual experiences do not predict another person’s results.
Discussion prompts: What questions are useful when comparing benefits and risks with a clinician? Which insurance or pharmacy terms are hardest to understand?
Talking about GLP-1 use and everyday experiences
Good forum conversations make room for practical realities: how people organize questions for appointments, think about balanced meals, handle meal planning, track general wellbeing, discuss nausea or constipation with their clinicians, and understand prescription directions. Members can share what they experienced without advising others to change a prescription, combine drugs, buy unapproved substances, or use a specific dose.
Common GLP-1 discussion topics
- Starting treatment: what to ask your prescriber, what medication labels mean, and planning follow-up care.
- Side effects: describing experiences clearly, recognizing that severe or persistent symptoms need medical attention.
- Weight-management routines: conversations around food, hydration, exercise, strength training, and sleep.
- Plateaus and expectations: what progress means beyond a single scale reading and why outcomes vary.
- Cost and access: insurance terminology, prior authorizations, pharmacy experience and transparent provider reviews.
- Research literacy: reading clinical trials, distinguishing approved medications from investigational compounds and recognizing marketing claims.
Where does retatrutide fit?
Retatrutide is an investigational medication studied for its activity at multiple metabolic receptors, including GLP-1. It should not be described as an FDA-approved brand equivalent to Ozempic or Zepbound. Discussion of preliminary clinical evidence is welcome, but self-experimentation and claims of established safety or approved use are inappropriate.
Side effects, safety and when to seek help
Gastrointestinal side effects such as nausea, vomiting, diarrhea or constipation are frequently discussed with GLP-1 medicines. Prescription labels include important contraindications, warnings and monitoring considerations that vary by product. Persistent vomiting, dehydration, severe abdominal pain, possible allergic reactions or other worrying symptoms should be assessed promptly by a qualified clinician. This guide is not a substitute for individualized clinical care.
Frequently asked GLP-1 questions
Is Mounjaro the same as Zepbound?
They share tirzepatide as their active ingredient, but are different branded products with different labeled uses. Discuss your actual prescription with your clinician.
Are Ozempic and Wegovy the same thing?
Both contain semaglutide, but they are not interchangeable in how their labeled indications and product instructions are described.
Is every GLP medication a GLP-1 drug?
Not necessarily. GLP is a broader peptide/hormone family, while GLP-1 is a particular receptor pathway. Tirzepatide is a dual GIP/GLP-1 receptor agonist.
Can I ask the forum for dosing advice?
You can ask about how to understand an official drug label or what to discuss with your prescriber, but members should not prescribe doses, offer injection instructions for unapproved products or recommend unsupervised changes.
How can I get reliable answers?
Describe the medication and question accurately, distinguish personal experiences from medical claims, and include reliable sources for claims about safety, efficacy or approvals.
Explore common GLP-1 questions
Looking for specific answers? Browse our GLP-1 Questions & Answers library covering Ozempic vs Mounjaro, semaglutide vs tirzepatide, nausea, costs, insurance, and weight-loss plateaus.
Join the discussion
Our GLP-1 discussion forum covers medication research and comparisons, experiences and side effects, provider reviews, and beginner questions. You can read publicly; sign in to ask questions and join conversations.
Trusted medical sources
- NIDDK — Prescription Medications to Treat Overweight & Obesity
- FDA — GLP-1 medicines overview and approved brands
- DailyMed — current U.S. product labeling
Last editorial review: October 23, 2026. Product labels and approvals may change. Verify with FDA and DailyMed before relying on any treatment-related claim.